Skip to content
lifestyle.claritypointe.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
GENFIT S.A.
GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
September 9, 2026
GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026
September 3, 2026
GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
May 26, 2026
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
May 26, 2026
GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
May 22, 2026
GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)
April 20, 2026
GENFIT Announces Publication of the 2025 Universal Registration Document
April 7, 2026
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
April 2, 2026
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
March 9, 2026
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales
February 13, 2026